Venus Remedies receives first patent for a novel antibiotic product

22 May 2012 Evaluate

Venus Remedies has received its first patent for a novel antibiotic combination of carbapenem and amino glycoside from Companies and Intellectual Property Registration Office (CIPRO), South Africa. Pioneering into antibacterial portfolio, Venus has added another international patent to its basket for the antibiotic combination rationally designed to result in a pharmaceutical low dose. Overall, Venus is enjoying a total tally of more than 80 patents for its innovative research products across the globe.

Venus Medicine Research Centre (VMRC) is constantly working on innovating new technologies and drugs for eradicating the most fatal disease in the world. The company has made amazing progress to treat serious fatal mixed multi-bacterial infectious diseases through their novel antibiotic combination of carbapenem and aminoglycoside. Having received this patent grant from CIPRO, South Africa, the company is hopeful of capturing a major share in the market.

Novel antibiotic combination is suitable for the treatment of bacterial/ multi-bacterial infections, and is particularly suitable for catering to the needs of all age groups ranging from the neonates, children, immune compromised patients, and the ones prone to serious fatal mixed multi-bacterial infectious disease.

Venus Remedies Share Price

322.00 33.75 (11.71%)
31-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1462.50
Dr. Reddys Lab 5784.50
Cipla 1451.25
Zydus Lifesciences 1001.15
Lupin 1587.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.